Cellular Classification
One clinicopathologic staging system involves evaluation
of tumor specimens obtained prior to therapy for the amount of stromal development, the degree of
neuroblastic maturation, and the mitosis-karyorrhexis index of the neuroblastic
cells.[1,2] Favorable and unfavorable prognoses are defined on the bases of
these histologic parameters and on patient age. The prognostic significance of
this classification system, and of related systems using similar criteria, has
been confirmed in several studies.[1-3] Neuroblastoma containing many
differentiating cells, termed ganglioneuroblastoma, can have nodules of undifferentiated cells whose histology, along with MYCN amplification, determines prognosis.[4,5]
References
-
Shimada H, Ambros IM, Dehner LP, et al.: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86 (2): 364-72, 1999.
[PUBMED Abstract]
-
Shimada H, Umehara S, Monobe Y, et al.: International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92 (9): 2451-61, 2001.
[PUBMED Abstract]
-
Goto S, Umehara S, Gerbing RB, et al.: Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92 (10): 2699-708, 2001.
[PUBMED Abstract]
-
Kubota M, Suita S, Tajiri T, et al.: Analysis of the prognostic factors relating to better clinical outcome in ganglioneuroblastoma. J Pediatr Surg 35 (1): 92-5, 2000.
[PUBMED Abstract]
-
Peuchmaur M, d'Amore ES, Joshi VV, et al.: Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98 (10): 2274-81, 2003.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |